Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
about
Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerHuman epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slideCost-utility analyses of drug therapies in breast cancer: a systematic review.FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics.Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.The assessment of HER2 status in breast cancer: the past, the present, and the future.HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category.
P2860
Q34248282-F63C2554-087B-47B1-BCAF-9580AF81D434Q34511787-0315B0F1-C911-4F20-8734-25CDE62A945DQ35038694-16AFEFC3-B647-41D5-A85C-5E1A7191D0C3Q35343184-E010902F-A0DF-4121-BDCF-AA297A2E1DE1Q35929360-921C02CE-3EEC-4AF0-8A16-57FA49DE4C53Q36116276-7EFFF33E-C0A4-49F1-BF78-DC4D8148003AQ37406841-2152F65C-C133-4C8E-8E4B-331F09264056Q38241709-96C13FC4-DA3F-4A45-803A-B76763460D9DQ38326102-BD6591CE-D8E7-4E04-AF10-81A8CA874E35Q38377039-EEE929B4-E50C-4BA3-A336-FFD1588D686DQ38802932-7FD63F1C-A48A-4770-AF1C-BE124851A357Q48147789-597FF6E6-4233-46F7-BB26-F548136DFC89
P2860
Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Assessing the potential cost-e ...... ncer patients for HER2 status.
@en
Assessing the potential cost-e ...... ncer patients for HER2 status.
@nl
type
label
Assessing the potential cost-e ...... ncer patients for HER2 status.
@en
Assessing the potential cost-e ...... ncer patients for HER2 status.
@nl
prefLabel
Assessing the potential cost-e ...... ncer patients for HER2 status.
@en
Assessing the potential cost-e ...... ncer patients for HER2 status.
@nl
P2093
P2860
P356
P1433
P1476
Assessing the potential cost-e ...... ncer patients for HER2 status.
@en
P2093
Bruce Wang
Deepa Lalla
Edith A Perez
Joseph B Babigumira
Louis P Garrison
Melissa Brammer
P2860
P304
P356
10.1002/CNCR.28196
P407
P577
2013-06-17T00:00:00Z